Heather Bradley, MPH

Executive Director, Regulatory Affairs
Acadia Pharmaceuticals Inc

Poster(s):

• 058: Population Pharmacokinetic Modelling to Predict Trofinetide Exposure & Exposure-Response Safety Analyses in Girls With Rett Syndrome Aged 2–4 Years
  Sunday, September 10, 2023

  5:00 PM - 7:00 PM PT

• 072: Population Pharmacokinetic Modelling to Confirm Weight-Based Banded Dosing & Exposure-Response Efficacy Analyses to Support Trofinetide Treatment in Rett Syndrome
  Sunday, September 10, 2023

  5:00 PM - 7:00 PM PT

• 132: Limited Potential for Interactions Between Trofinetide, a New Treatment for Rett Syndrome, & Drugs Metabolized By CYP3A4
  Monday, September 11, 2023

  5:00 PM - 7:00 PM PT

• 178: In Silico Physiologically Based Pharmacokinetic Model of the Effect of Hepatic Impairment on Trofinetide Exposures
  Monday, September 11, 2023

  5:00 PM - 7:00 PM PT